Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialize oral covalent inhibitors.

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Verastem Oncology’s VS-7375.

Stevanato Group has secured €200 million in financing intended to support its ongoing capital expenditure projects in ...

AstraZeneca has announced a $50 billion investment in the United States by 2030, creating tens of thousands of new, highly ...

BGENE-DMD is designed to treat Duchenne muscular dystrophy (DMD) via a one-time administration in a single AAV.

Ipsen, a global specialty care biopharmaceutical company, has made the following changes to its Executive Committee: ...

Jeff Sheehan, Managing Partner at Trinity Capital, Spark’s developer, commented, “Coriolis Pharma’s decision to establish ...

Abzena, an end-to-end integrated CDMO and CRO, has appointed Geoffrey M. Glass as Chief Executive Officer (CEO), effective ...

Solvias' Center of Excellence for biologics and novel modalities in Research Triangle Park, North Carolina, is now cGMP ready ...

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...

Operational strategies to optimize efficiency and cost effectiveness, and secure an unbroken chain of custody from ...

Sanner has opened its first U.S.-based production facility in Greensboro, North Carolina, just weeks after commencing initial ...